Introduction {#s1}
============

An estimated 29.1 million people in the U.S. have diabetes mellitus, which equates to 9.3% of the population ([@B1]). Of patients with diabetes, 60% to 70% have neuropathy, which manifests as a wide range of symptoms depending on the affected nerves and the targets of innervation. More than half of all major lower-limb amputations in the U.S. are associated with diabetes ([@B2]).

Diabetic neuropathy is multifactorial but has a pathogenesis strongly associated with microvascular dysfunction, increased polyol pathway activation, elevated reactive oxygen species (ROS), and chronic inflammation ([@B3],[@B4]). Pharmacological strategies exist to target this pathology. Inhibition of neutral endopeptidase permits the accumulation of vasodilatory peptides and decreases oxidative stress, which preserves vascular function and prevents diabetic neuropathy ([@B4]). Inhibition of aldose reductase improves neuropathy by attenuating the diabetes-associated decline of nerve conduction velocity ([@B3],[@B5]) and hyperglycemia-induced oxidative stress, in part by maintaining glutathione concentrations ([@B6]). Lipoic acid (LA) decreases oxidative stress by direct free radical scavenging and by regenerating other intracellular antioxidants, including glutathione ([@B7]); it also has been shown to improve diabetic neuropathy by not only attenuating oxidative stress ([@B8]) but also normalizing endoneurial blood flow ([@B9]) and improving vascular function ([@B10]). Similarly, omega-3 polyunsaturated fatty acids (ω-3 PUFAs), although controversial, have anti-inflammatory effects and attenuate diabetic symptoms (c.f. ref. [@B11]).

Innervation of the bone marrow regulates the release of progenitor and immune cell populations from the bone marrow. Activation of sympathetic noradrenergic nerves permits vascular progenitor cells and immune cells to enter the circulation and perform systemic surveillance of peripheral tissues ([@B12]). We previously demonstrated that diabetic neuropathy manifests in the bone marrow, resulting in decreased total innervation, sensory innervation, and adrenergic innervation, which alter stromal cell secretion of cytokines and growth factors, leading to a shift toward increased generation of myeloid cells but reduced numbers of endothelial progenitor cells ([@B13]--[@B15]). Both streptozotocin (STZ)-induced diabetic and type 2 diabetic (T2D) rats exhibited bone marrow neuropathy, which was concluded to contribute to diabetic retinopathy ([@B14]).

The purpose of this study was to evaluate the changes found in the bone marrow microenvironment of STZ-induced diabetic rats following administration of selected treatments that have been shown to prevent diabetic peripheral neuropathy. We assessed the presence of neuropathic changes by testing thermal nociceptive response, motor nerve conduction velocity (MNCV), and sensory nerve conduction velocity (SNCV) in the sciatic nerve. We evaluated the bone marrow microenvironment in STZ-induced diabetic rats by examining changes in neural immunoreactivity, growth factors, and cytokines within the bone marrow and by measuring changes in gene expression in bone marrow--derived progenitor cells.

Research Design and Methods {#s2}
===========================

Pharmacological Agents {#s3}
----------------------

Unless stated otherwise, all chemicals used in these studies were obtained from Sigma Chemical (St. Louis, MO). Ilepatril (Ile) was a generous gift from Dr. Jurgen Punter (Sanofi, Paris, France). Fidarestat (Fid) was a generous gift from Sanwa Kagaku Kenkyusho (Kariya, Aichi, Japan). Insulin was purchased from Sanofi.

Animal Studies {#s4}
--------------

Male, 12-week-old Sprague-Dawley rats (Harlan, Indianapolis, IN) were housed in a certified animal care facility, with food (\#7001; Harlan Teklad, Madison, WI) and water provided ad libitum. All institutional (approval ACURF no. 1202032) and National Institutes of Health guidelines for use of animals were followed. Diabetes was induced by intraperitoneal injection of STZ (55 mg/kg in 0.9% sodium chloride, adjusted to pH 4.0, with 0.2 mol/L sodium citrate). Control rats were injected with vehicle alone. Diabetes was verified 48 h later by evaluating blood glucose concentrations using glucose dehydrogenase--based reagent strips (Aviva Accu-Chek; Roche, Mannheim, Germany). Rats with a blood glucose concentration of ≥300 mg/dL (11.1 mmol/L) were considered diabetic.

Treatment Conditions {#s5}
--------------------

Two weeks after the verification of diabetes, five groups were established: *1*) untreated nondiabetic (Con group, *n* = 8); *2*) untreated diabetic (DM group, *n* = 11); *3*) diabetic treated with Ile (DM + Ile group, *n* = 10); *4*) diabetic treated with Fid and LA (DM + Fid + LA group, *n* = 10); and *5*) diabetic treated with insulin and menhaden oil (Menh) (DM + Ins + Menh group, *n* = 7). The treatment dosages are listed in [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0433/-/DC1). With the exception of insulin and Menh, all treatment compounds were mixed in the meal form of the diet, which was subsequently pelleted and dried in a vacuum oven for 16 h at 37°C. The diet containing Menh was purchased from Research Diets (New Brunswick, NJ). The treatment phase of the study lasted 6 weeks, and the total duration of diabetes was 8 weeks. Elevated glycated hemoglobin was significantly attenuated only in the DM + Ins + Menh group.

Thermal Nociceptive Response {#s6}
----------------------------

The day before the terminal studies, thermal nociceptive response in the hind paw was measured using the Hargreaves method, as previously described ([@B16]). Four measurements were made for each hind paw, and the mean of the measurements was used as the response time. Afterward, MNCV and SNCV in the sciatic nerve were determined.

MNCV and SNCV {#s7}
-------------

MNCV was determined as previously described using a noninvasive procedure in the sciatic-posterior tibial conducting system in a temperature-controlled environment ([@B16]). SNCV was determined using the digital nerve to the second toe, as previously described ([@B16]).

Isolation of Thy-1^+^ Cells From Bone Marrow {#s8}
--------------------------------------------

Rats were anesthetized with 50 mg/kg intraperitoneal Nembutal (Abbott Laboratories, North Chicago, IL) and killed by exsanguination. After death, hind limb bones were removed, placed in 10-mL containers filled with PBS, packed on wet ice, and shipped overnight to the University of Florida. Upon receipt, the femoral marrow compartment was flushed with 10 mL of PBS and the cells pelleted by centrifugation. The supernatant was flash-frozen for later cytokine quantification. The cells then were treated with ammonium chloride (STEMCELL Technologies Inc., Vancouver, BC, Canada) to remove any contaminating red blood cells and resuspended in PBS per the instructions of a customized negative-selection kit (STEMCELL Technologies) used to magnetically deplete CD4^+^, CD5^+^, CD8a^+^, and OX-43^+^ cells. The cells then were enriched for CD90^+^ (Thy-1) cells using a positive selection magnet separation kit (STEMCELL Technologies) with an antibody for CD90/Thy-1.

Cytokine Quantification {#s9}
-----------------------

Concentrations of cytokines in the bone marrow supernatant were determined using microsphere-based suspension microarray technology (AssayGate, Ijamsville, MD). This methodology is the Luminex bead-based immunoassay platform. In brief, multiple analytes from a single sample of bone marrow supernatant were determined using the Bio-Plex 200 Bead Reader System (Bio-Rad, Hercules, CA). Microparticles were conjugated to differing concentrations of two fluorophores to generate distinct bead sets. Each bead set was coated with capture antibody specific for one analyte. Captured analyte was detected using a biotinylated detection antibody and streptavidin--phycoerythrin. The bead analyzer was a dual-laser, flow-based sorting and detection platform. One laser was bead-specific and the other determined the magnitude of phycoerythrin-derived signal, which is in direct proportion to the amount of analyte bound. Each sample was tested in duplicate. The results were expressed as picograms per milliliter. Analyte concentrations below the threshold of detection were excluded from the analysis.

Real-Time Quantitative RT-PCR {#s10}
-----------------------------

Bone marrow--derived Thy-1^+^ cells were homogenized in TRIzol reagent (Invitrogen), and RNA was isolated according to the manufacturer's instructions. First-strand cDNA was synthesized from isolated RNA using an iScript cDNA synthesis kit (Bio-Rad). Prepared cDNA was mixed with Gene Expression Master Mix (Applied Biosystems, Carlsbad, CA) and the respective gene-specific TaqMan assays (Life Technologies) and subjected to real-time PCR quantification using the 7500 Fast Real-Time PCR System (Applied Biosystems). Genes of interest included NADPH oxidase-2 (NOX-2, Rn00576710_m1), intracellular adhesion molecule-1 (ICAM, Rn00564227_m1), interleukin (IL)-6 (IL-6, Rn01410330_m1), IL-1β (Rn00580432_m1), nuclear factor κ light chain enhancer of activated B cells (NF-κB1, Rn01399583_m1), inducible nitric oxide synthase (NOS-2, Rn00561646_m1), Toll-like receptor 4 (TLR-4, Rn00569848_m1), angiotensin II receptor type 1a (AgtR1a, Rn02758772_s1), and angiotensin I--converting enzyme 2 (ACE2, Rn01416293_m1). All reactions were performed in triplicate. Relative mRNA levels were calculated using the comparative threshold method, normalized to mitochondrial ribosomal protein L-19 (MRPL-19, Rn01533663_m1).

Immunohistochemistry {#s11}
--------------------

Formalin-fixed femurs were processed as previously described ([@B14]). Briefly, bones were decalcified, embedded in paraffin, and sectioned on a rotary microtome at 4 μm. Sections were placed on adhesive slides, deparaffinized, and submitted to antigen-retrieval protocols ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0433/-/DC1)). Following pretreatments, standard avidin-biotin complex staining steps were performed at room temperature using a Dako Autostainer. After blocking nonspecific protein with nonimmune goat serum (Vector Laboratories, Burlingame, CA), sections were incubated with an avidin (Vector Laboratories)/biotin (Sigma-Aldrich) blocking system. Sections were incubated with antibodies ([Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0433/-/DC1)) followed by R.T.U. VectaStain Elite ABC Reagent (Vector) and were developed with NovaRED (Vector Laboratories) followed by counterstain in Gill 2 hematoxylin (Richard Allen, Kalamazoo, MI). Slides then were dehydrated, cleared, and placed on a slide under a coverslip with Flotex Permount mounting media.

Aperio and Positive Pixel Count Algorithm {#s12}
-----------------------------------------

Stained femurs on slides were scanned using an Aperio CS slide scanning system with a Spectrum Plus information management system (Aperio Technologies, Inc., Vista, CA). The ImageScope program (Aperio) was used to quantify positive staining in two regions of marrow (distal middle and middle) using the Positive Pixel Count algorithm (Aperio). Positive pixels were determined by a range of hues, saturations, and intensities of NovaRED. Negative controls for all targets were analyzed to ensure that the algorithm detected minimal positive pixels. Adiposity of the bone marrow was assessed in a representative region within the middle distal femur that spanned from the medial cortex to the lateral cortex and constituted an area between 1 and 1.5 mm^2^. Adipose remains unstained and is thus not considered positive or negative by the algorithm. Therefore, we subtracted the area of positive and negative pixilation from the total area of the selected region. We were careful to select regions devoid of nonstained artifact, for example, tears in the tissue resulting from processing.

Data Analysis {#s13}
-------------

All data were analyzed for outliers before treatment comparisons. Comparisons between the groups were assessed using a one-way ANOVA followed by the Tukey post hoc test. *P* \< 0.05 was considered significant.

Results {#s14}
=======

Morphologic Characteristics of Experimental Rats {#s15}
------------------------------------------------

Blood glucose, glycated hemoglobin, and body weight before and after the study are shown in [Table 1](#T1){ref-type="table"}. STZ-induced diabetes was associated with decreased body weight in all groups, which was prevented only in the DM + Ins + Menh group. Likewise, blood glucose and glycated hemoglobin were elevated in all STZ-induced diabetic groups except DM + Ins + Menh.

###### 

Effect of treating diabetic rats with Ile, Fid + LA, or Ins + Menh on change in body weight, blood glucose, and HbA~1c~

                          Con (*n* = 9)   DM (*n* = 10)                                DM + Ile (*n* = 10)                          DM + Fid + LA (*n* = 10)                     DM + Ins + Menh (*n* = 10)
  ----------------------- --------------- -------------------------------------------- -------------------------------------------- -------------------------------------------- ------------------------------------------
  Weight (g)                                                                                                                                                                     
   Start                  337 ± 4         337 ± 3                                      338 ± 3                                      338 ± 2                                      337 ± 2
   End                    445 ± 6         357 ± 14[\*](#t1n1){ref-type="table-fn"}     360 ± 16[\*](#t1n1){ref-type="table-fn"}     315 ± 13[\*](#t1n1){ref-type="table-fn"}     428 ± 5[†](#t1n2){ref-type="table-fn"}
  Blood glucose (mg/dL)   141 ± 5         584 ± 13[\*](#t1n1){ref-type="table-fn"}     539 ± 27[\*](#t1n1){ref-type="table-fn"}     515 ± 19[\*](#t1n1){ref-type="table-fn"}     205 ± 52[†](#t1n2){ref-type="table-fn"}
  HbA~1c~ (%)             7.3 ± 0.5       14.3 ± 1.8[\*](#t1n1){ref-type="table-fn"}   12.4 ± 1.0[\*](#t1n1){ref-type="table-fn"}   13.2 ± 1.5[\*](#t1n1){ref-type="table-fn"}   8.8 ± 1.5[†](#t1n2){ref-type="table-fn"}
  HbA~1c~ (mmol/mol)      56 ± 3.8        133 ± 16.7[\*](#t1n1){ref-type="table-fn"}   112 ± 9.0[\*](#t1n1){ref-type="table-fn"}    121 ± 13.8[\*](#t1n1){ref-type="table-fn"}   73 ± 12.4[†](#t1n2){ref-type="table-fn"}

Data are presented as mean ± SEM.

*P* \< 0.05 compared with control rats;

*P* \< 0.05 compared with diabetic rats. Values in parentheses indicate the number of experimental animals.

Thermal Nociceptive Response and Nerve Conduction Velocities {#s16}
------------------------------------------------------------

Neuropathy results in altered conduction velocities and dampened sensitivity to noxious stimuli. Compared with nondiabetic controls, untreated diabetes was associated with decreased MNCV and SNCV in the sciatic nerve conducting system and delayed response to noxious heat. All treatment conditions prevented nerve dysfunction associated with STZ-induced diabetes ([Table 2](#T2){ref-type="table"}).

###### 

Effect of treating diabetic rats with Ile, Fid + LA, or Ins + Menh on MNCV, SNCV, and thermal sensitivity

                            Con (*n* = 9)   DM (*n* = 10)                                DM + Ile (*n* = 10)                         DM + Fid + LA (*n* = 10)                    DM + Ins + Menh (*n* = 10)
  ------------------------- --------------- -------------------------------------------- ------------------------------------------- ------------------------------------------- -------------------------------------------
  MNCV (m/s)                56.2 ± 2.1      40.8 ± 1.2[\*](#t2n1){ref-type="table-fn"}   52.9 ± 1.6[†](#t2n2){ref-type="table-fn"}   54.2 ± 1.4[†](#t2n2){ref-type="table-fn"}   55.1 ± 3.0[†](#t2n2){ref-type="table-fn"}
  SNCV (m/s)                19.8 ± 0.3      17.6 ± 0.2[\*](#t2n1){ref-type="table-fn"}   19.0 ± 0.2[†](#t2n2){ref-type="table-fn"}   18.9 ± 0.2[†](#t2n2){ref-type="table-fn"}   19.6 ± 0.2[†](#t2n2){ref-type="table-fn"}
  Thermal sensitivity (s)   12.8 ± 0.6      19.0 ± 1.0[\*](#t2n1){ref-type="table-fn"}   12.3 ± 0.5[†](#t2n2){ref-type="table-fn"}   13.2 ± 0.6[†](#t2n2){ref-type="table-fn"}   11.1 ± 0.5[†](#t2n2){ref-type="table-fn"}

Data are presented as mean ± SEM.

*P* \< 0.05 compared with control rats;

*P* \< 0.05 compared with diabetic rats. Values in parentheses indicate the number of experimental animals.

Quantification of Tyrosine Hydroxylase Immunoreactivity {#s17}
-------------------------------------------------------

Tyrosine hydroxylase (TH) is a rate-limiting enzyme in catecholamine biosynthesis ([@B17]), and its activity is a measure of the number of sympathetic neurons and an index of sympathetic nervous system activity ([@B18]). [Figure 1*A*](#F1){ref-type="fig"} shows representative TH staining in the distal middle femoral marrow before (top gray images) and after analysis (bottom blue images) by Aperio using the Positive Pixel Count algorithm. Positive staining is depicted by yellow (weak positive), orange (middle positive), and red (strong positive). Semiquantification of the staining for TH revealed that STZ-induced diabetes was associated with an increased ratio of strong-positive immunoreactivity (i.e., Nsr = \[number of strong-positive pixels\] ÷ \[number of all positive pixels\]), which is shown in [Fig. 1*B*](#F1){ref-type="fig"}. We interpret this finding as an indicator of increased neuronal injury and subsequent successful repair or preemptive neurogenesis. The increased strong-positive immunoreactivity was significantly attenuated in the DM + Ile and the DM + Fid + LA groups.

![*A*: TH staining of middle distal femoral marrow. The images show representative TH staining before (top gray images) and after quantification (bottom blue images) by Aperio using the Positive Pixel Count algorithm. In the markup images, a positive stain is indicated by yellow (weak positive), orange (middle positive), and red (strong positive). There were 7--12 animals per group. Scale bar = 300 µM. *B*: Ratio of strong-positive TH pixels to total positive pixels in the middle distal femur. Data represent mean ± SD. \*Significant differences between groups (*P* \< 0.05).](db140433f1){#F1}

Quantification of Somatostatin Immunoreactivity {#s18}
-----------------------------------------------

Somatostatin (SST) is a neurotransmitter that exerts anti-inflammatory and immunosuppressive effects ([@B19]). Immunostaining for SST ([Fig. 2*A*](#F2){ref-type="fig"}) revealed a trend similar to that of TH. STZ-induced diabetes was associated with increased ratio of strong-positive immunoreactivity in the femoral marrow, which was attenuated only in the DM + Fid + LA group ([Fig. 2*B*](#F2){ref-type="fig"}).

![*A*: SST staining of middle distal femoral marrow. Images show representative SST staining before (top gray images) and after quantification (bottom blue images) by Aperio using the Positive Pixel Count algorithm. In the markup images, a positive stain is indicated by yellow (weak positive), orange (middle positive), and red (strong positive). There were 7--12 animals per group. Scale bar = 300 µM. *B*: Ratio of strong-positive SST pixels to total positive pixels in the middle distal femur. Data represent mean ± SD. \*Significant differences between groups (*P* \< 0.05).](db140433f2){#F2}

Quantification of Neuropeptide Y Immunoreactivity {#s19}
-------------------------------------------------

Neuropeptide tyrosine (NPY) functions to increase progenitor cell populations and maintain their undifferentiated status in the bone marrow ([@B20]). NPY immunostaining in STZ-induced diabetes also was associated with an increased ratio of strong-positive immunoreactivity in the femoral marrow ([Fig. 3*A*](#F3){ref-type="fig"}), analogous to TH and SST. The increase of NPY immunoreactivity associated with STZ-induced diabetes was attenuated in the DM + Fid + LA and the DM + Ins + Menh groups ([Fig. 3*B*](#F3){ref-type="fig"}).

![*A*: NPY staining of middle distal femoral marrow. Images show representative NPY staining before (top gray images) and after quantification (bottom blue images) by Aperio using the Positive Pixel Count algorithm. In the markup images, a positive stain is indicated by yellow (weak positive), orange (middle positive), and red (strong positive). There were 7--12 animals per group. Scale bar = 300 µM. *B*: Ratio of strong-positive NPY pixels to total positive pixels in the middle distal femur. Data represent mean ± SD. \*Significant differences between groups (*P* \< 0.05).](db140433f3){#F3}

Quantification of Calcitonin Gene-Related Peptide and 8-Hydroxy-2′-Deoxyguanosine Immunoreactivity {#s20}
--------------------------------------------------------------------------------------------------

In an effort to assess whether Ile decreased vasodilatory peptide degradation, we performed immunohistochemistry for the peptide and neurotransmitter calcitonin gene-related peptide (CGRP). However, we did not detect any significant differences within the bone marrow between the experimental groups ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0433/-/DC1)).

A possible mechanism for the beneficial effect of Fid + LA and Menh + Ins treatments is reduction of oxidative stress. We measured concentrations of 8-hydroxy-2′-deoxyguanosine, a product of DNA oxidation, within the bone marrow; however, we did not detect any differences in the immunoreactivity between experimental groups.

Bone Marrow Adiposity {#s21}
---------------------

Marrow adipose is proposed to have multiple functions, including autocrine/paracrine/endocrine support as well as a regulatory role in stem cell differentiation. STZ-induced diabetes was associated with a loss of bone marrow adiposity, which corroborated our previous findings ([@B13]). The loss of femoral marrow adiposity associated with STZ-induced diabetes was prevented in the DM + Ile and DM + Ins + Menh groups ([Fig. 4](#F4){ref-type="fig"}).

![*A*: Treatments restore bone marrow adiposity. Adipocytes remain unstained in sections of middle distal femur stained with hematoxylin and eosin; they appear as white ovals and are indicated by arrowheads. Scale bar = 500 μM. *B*: Quantification of femoral marrow adiposity. Area of adiposity was determined by subtracting the area of positive and negative pixilation from the total area of a designated region. Data represent mean ± SD. \*Significant differences between groups (*P* \< 0.05).](db140433f4){#F4}

Bone Marrow Cytokines {#s22}
---------------------

The supernatant from STZ-induced diabetic bone marrow was associated with elevated proinflammatory cytokines and proteases. Significant differences between groups were found for the following cytokines (picograms per milliliter): matrix metalloproteinase (MMP)-2 ([Fig. 5*A*](#F5){ref-type="fig"}), IL-1β ([Fig. 5*C*](#F5){ref-type="fig"}), macrophage colony-stimulating factor (Con group 4.24 ± 0.4 vs. DM group 5.24 ± 0.96), IGF-I (Con group 809.7 ± 329.9 vs. DM group 416.6 ± 195.9), IGF-binding protein-3 (DM group 39,760.8 ± 4,758.6 vs. DM + Fid + LA group 29,006.7 ± 4,574.1), IL-3 (DM group 47.5 ± 26.8 vs. DM + Ins + Menh group 230.9 ± 160.6), and IL-10 (DM group 89.41 ± 66.1 vs. Con group 16.56 ± 6.52, DM + Ile group 10.04 ± 0.01, DM + Fid + LA group 28.75 ± 14.5, and DM + Ins + Menh group 16.83 ± 12.69) (*P* \< 0.05). No significant differences between groups were found for MMP-9, stem cell factor, stromal cell-derived factor 1a, granulocyte colony-stimulating factor, IL-6, tumor necrosis factor-α, or vascular endothelial growth factor. Despite the dramatic difference between groups for granulocyte/macrophage colony stimulating factor (GM-CSF) ([Fig. 5*A*](#F5){ref-type="fig"}), we were not able to perform statistics because of the undetectably low concentrations from nearly all samples in the control and treated groups.

![GM-CSF (*A*), MMP-2 (*B*), and IL-1β (*C*) in femoral marrow. Data represent mean ± SD. Statistics for GM-CSF (*A*) could not be applied because of low detection in the nondiabetic control (Con) and treatment groups. \*Significant difference from all other groups (*P* \< 0.05). ND, not detected.](db140433f5){#F5}

Progenitor Cell Gene Expression {#s23}
-------------------------------

STZ-induced diabetes was associated with a robust increase in proinflammatory gene expression in progenitor cells, which corroborated our previous findings ([@B13]). All treatment conditions prevented this STZ-induced diabetes--associated increase. Significant differences were found between groups for NOX-2 ([Fig. 6*A*](#F6){ref-type="fig"}), NF-κB1 ([Fig. 6*B*](#F6){ref-type="fig"}), and NOS-2 ([Fig. 6*C*](#F6){ref-type="fig"}). No significant differences were found between groups for ACE2 ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0433/-/DC1)), AgtR1a ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0433/-/DC1)), IL-6, or TLR-4.

![NOX-2 (*A*), NF-κB1 (*B*), and NOS-2 (*C*) gene expression from Thy1^+^ cells isolated from femurs. Data represent mean ± SD. \*Significant difference from all other groups (*P* \< 0.05).](db140433f6){#F6}

Discussion {#s24}
==========

To our knowledge, this study is the first to demonstrate a reversal of diabetes-associated alterations within the bone marrow, despite hyperglycemia and hypoinsulinemia. The diabetic phenotype of the bone marrow was characterized by an increased proportion of strong-positive immunoreactivity for TH, SST, and NPY ([Figs. 1](#F1){ref-type="fig"}--[3](#F3){ref-type="fig"}). These changes are consistent with preemptive neurogenesis and/or compensatory repair ([@B21],[@B22]) following injury. The diabetic phenotype of the bone marrow was further characterized by decreased marrow adiposity ([Fig. 4](#F4){ref-type="fig"}), a highly proinflammatory bone marrow microenvironment (i.e., elevated IL-1β, MMP-2, and GM-CSF) ([Fig. 5](#F5){ref-type="fig"}), and increased proinflammatory gene expression (i.e., NOX-2, NF-κB1, NOS-2) ([Fig. 6](#F6){ref-type="fig"}) in bone marrow--derived progenitor cells. All therapies that we investigated prevented peripheral neuropathy ([Table 2](#T2){ref-type="table"}) and showed high efficacy in attenuating the respective STZ-induced diabetes--associated alterations of the bone marrow.

Currently approved and available therapies for diabetic neuropathy are symptomatic as opposed to disease modifying. With the exception of rigorous glycemic control, there is currently no approved treatment to reverse, or even slow, the progression of diabetic neuropathy. Vascular dysfunction and decreased endoneurial blood flow precede neuropathy (i.e., decreased nerve conduction velocity) in STZ-induced diabetic rats ([@B4]). Herein we identified novel ways to prevent regional neuropathic changes in the bone marrow in this type 1 diabetic (T1D) model.

One of the primary drug targets in this study was neutral endopeptidase, which metabolizes vasodilatory peptides including the natriuretic peptides, bradykinin, and CGRP. Inhibition of neutral endopeptidase with Ile attenuates STZ-induced diabetes--associated decline of endoneurial blood flow and subsequent neuropathy by preventing degradation of vasoactive peptides and decreasing oxidative stress ([@B4]). Consistent with previous studies of other tissues, we demonstrated that neutral endopeptidase inhibition prevents the development of bone marrow pathology associated with STZ-induced diabetes. However, we expected this treatment to facilitate the accumulation of CGRP concentrations in the bone marrow, which we did not observe. We also did not see an increase of CGRP immunoreactivity in the untreated STZ-induced diabetic group, suggesting that CGRP-expressing neurons are not yet affected by the short duration of disease examined in this study. Although we did not detect differences for CGRP, neutral endopeptidase has many other targets that may have been improved with Ile, including bradykinin and the natriuretic peptides.

Ile is also an ACE inhibitor, which has vasomotor benefits. We found that ACE2, a component of the beneficial arm of the renin-angiotensin system, was highest in the Ile-treated group, followed by the Con group ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0433/-/DC1)), as expected. In fact, ACE2 gene expression was detectable only in these two groups, rendering statistical comparison with untreated diabetes impossible. AgtR1a mRNA expression was highest in the DM followed by the Con groups and was undetectable in the DM + Ile group ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0433/-/DC1)), as expected. However, none of these differences reached statistical significance.

Aldose reductase was another primary drug target chosen to attenuate oxidative stress. It is the first enzyme in the polyol pathway and catalyzes the reduction of glucose to sorbitol. Increased flux through the polyol pathway results in redox imbalance and oxidative stress due in part to lower concentrations of glutathione ([@B6]). Consequently, aldose reductase inhibition attenuates the T1D- and T2D-associated decline of nerve conduction velocity ([@B3],[@B5]) and hyperglycemia-induced oxidative stress, maintaining glutathione concentrations ([@B6]). By maintaining redox balance, aldose reductase inhibition also decreases the expression of nuclear factor-κB ([@B23]), which is a redox-sensitive transcription factor that increases the production of proinflammatory cytokines and chemokines ([@B24]). These studies are consistent with our finding that aldose reductase inhibition prevented the STZ-induced diabetes--associated phenotype in the bone marrow.

Another drug target was LA, which in many clinical trials has shown efficacy for the treatment of chronic inflammatory diseases, including diabetes ([@B10]). More specifically, LA improves diabetic neuropathies via attenuating oxidative stress ([@B8]), normalizing endoneurial blood flow ([@B9]), and improving vascular function ([@B25]). The effect of LA on oxidative stress occurs by direct free radical scavenging and by the regeneration of other intracellular antioxidants, including glutathione ([@B7]). Here we showed that these effects extend to the STZ-induced diabetic bone marrow.

ω-3 PUFAs exhibit anti-inflammatory properties (c.f. ref. [@B11]) and attenuate MMP-2 and MMP-9 expression in macrophages ([@B26]). Two notable ω-3 PUFAs are eicosapentaenoic acid and docosahexaenoic acid. Both readily incorporate into cell membranes, attenuate inflammation, and are enriched in Menh. We are aware of only one study that investigated the effect of Menh on peripheral neuropathy ([@B16]). Consistent with that study, our results suggest that Menh improved diabetic neuropathy, presumably because of the high proportion of ω-3 PUFAs and their anti-inflammatory effects.

In fact, all of our treatment conditions may have contributed to decreasing bone marrow inflammation. All three treatments corrected the increase of bone marrow GM-CSF associated with STZ-induced diabetes. Experimentally, monocytes/macrophages generated ex vivo in the presence of GM-CSF are skewed toward the proinflammatory M1 phenotype ([@B27]--[@B29]). In addition, GM-CSF and IL-1β positively regulate one another to promote inflammation ([@B30],[@B31]). Therefore, suppressing GM-CSF would be expected to attenuate the production of proinflammatory monocytes/macrophages.

We also observed increased progenitor cell expression of mRNA for NOS-2 and NOX-2 in STZ-induced diabetes, which was corrected toward nondiabetic levels by all three treatments. NOX is a major source of superoxide in the vascular endothelium, and NOX-mediated overproduction of ROS is involved in the initiation and progression of diabetic vascular complications by decreasing the bioavailability of nitric oxide ([@B32],[@B33]). Inhibition of NOS-2 prevented diabetic vascular dysfunction in rats ([@B34]--[@B36]). Finally, both NOS-2 and NOX contribute to the accumulation of ROS, which causes senescence and impairs self-renewal of progenitor cells ([@B37]--[@B40]). These findings support our global hypothesis that marrow neuropathy manifests as microvascular complications by compromising the release and function of reparative progenitors. Accordingly, these findings support our overall hypothesis that the selected therapies improve the phenotype of bone marrow--derived progenitor cells, which attenuates diabetic microvascular complications.

Late-stage peripheral diabetic neuropathy is characterized by a loss of innervation ([@B41],[@B42]); however, the early stages of injury in the T1D bone marrow may be associated with preemptive or compensatory neurogenesis. We observed that 8 weeks of STZ-induced diabetes was associated with an increased proportion of strong-positive immunoreactivity for all neural pathways investigated. This putative neurogenesis could be mediated by the local bone marrow microenvironment via an increase of neurotrophic factors. Trophic substances are supplied by the target tissue, and the relative abundance of trophic factors may regulate the density of innervation of the target ([@B43]). In fact, increased neuropeptide concentrations are observed in the early stages of diabetic inflammation ([@B44],[@B45]).

We previously studied a T2D model that was associated with decreased TH and neurofilament 200 immunoreactivity in the marrow of the humerus ([@B14]). Here, in a T1D model, we observed an increase of strong-positive immunoreactivity for TH in the femur ([Fig. 1*B*](#F1){ref-type="fig"}). The disparity between the two studies is likely due to differences in the etiology of STZ-induced diabetes and T2D. For example, insulin is effectively absent in STZ-induced/T1D, whereas the concentrations of insulin present in T2D may be sufficient to attenuate neuropathy ([@B46],[@B47]). In fact, the magnitude of sympathetic neuroaxonal dystrophy is more severe in the STZ-induced diabetes than the T2D model ([@B46]), as predicted. Thus, it is possible that the severe neuropathic phenotype of the T1D model initiates a greater compensatory response, particularly in the early stages, which manifests as the observed increase in strong-positive immunoreactivity.

Another potential explanation for increased neurotransmitter expression early in STZ-induced diabetes is damage to neurons themselves. Injury (e.g., ischemic, mechanical, or epileptic) is well known to induce neurogenesis in various brain regions. Animal models of epilepsy exhibit neurogenesis in the dentate gyrus ([@B22]). In animal models of stroke, transient ischemia induces proliferation of progenitor cells that possess neuronal markers that were able to send axonal projections from the anterior cortex to the thalamus ([@B21]). We propose that a similar phenomenon consisting of early injury and compensatory neurogenesis occurs in the T1D bone marrow, which ultimately becomes inadequate and results in sustained injury, leading to denervation, characteristic of advanced diabetic neuropathy ([@B41],[@B42]).

Tan et al. ([@B48]) provided an additional explanation for the STZ-induced diabetes--associated increase in strong-positive neurotransmitter immunoreactivity. They described a STZ-induced diabetes--associated increase in length and head diameter of dendritic spines and increased density of mushroom-shaped spines of second-order nociceptive neurons in the dorsal horn. These alterations presumably would increase the volume of each affected neuropeptide-containing dendrite, resulting in increased neurotransmitter content and increased immunoreactivity. In addition, these morphologic changes in dendritic spines were mechanistically linked to neuropathic pain ([@B48]).

Our results for SST are analogous to those of TH. SST functions as a chemoattractant for primitive hematopoietic progenitor cells ([@B49]) and controls differentiation and migration of thymocytes ([@B50]). Whereas noradrenergic activation facilitates release of progenitor cells to the circulation, SST release may function to sequester progenitor cells in the bone marrow. This is consistent with our finding that the bone marrow of rats with STZ-induced diabetes and T2D sequesters progenitor cell populations, as opposed to facilitating their cyclic, regulated release into the circulation ([@B14]).

SST decreased the viability of and chemokine production from both activated and unstimulated human macrophages ([@B19]). In addition, SST inhibits chemokine-induced T-cell infiltration through collagen, presumably by inhibiting secretion of MMPs ([@B51]). It is possible that the increased strong-positive SST immunoreactivity with STZ-induced diabetes ([Fig. 2](#F2){ref-type="fig"}) occurs to suppress the proinflammatory milieu in the STZ-induced diabetic bone marrow ([Fig. 5](#F5){ref-type="fig"}).

Similar to our immunoreactivity data for TH and SST, strong-positive NPY immunoreactivity was increased with STZ-induced diabetes and was maintained at control values in the treatment conditions. Fehér et al. ([@B44]) described an early increase in NPY-immunoreactive nerve fibers in the alimentary tract of STZ-induced diabetic rats. Similar to our interpretation, they suggested a compensatory response to offset the depletion of neuropeptides associated with STZ-induced diabetes. Circulating NPY is elevated with chronic stress and sympathetic nervous system activation ([@B52]). However, NPY has curiously been shown to differentially influence the propagation of inflammation. For example, exogenous NPY decreases inflammation in sepsis models ([@B53]) and decreases activated macrophages ([@B54]) yet activates antigen-presenting cells ([@B55]). In addition, elevated NPY in the bone marrow may have beneficial effects in increasing progenitor cell populations and maintaining their undifferentiated status; NPY receptor type-1 activation was associated with increased mesenchymal progenitor cell populations ([@B20]).

In contrast to our findings, Garrett et al. ([@B56]) revealed an STZ-induced diabetes--associated decrease in NPY-like immunoreactivity in the sciatic nerve in a rat model of diabetic neuropathy (8 weeks), suggesting that neurogenesis may not occur in all peripheral nerves. However, similar to the current study, the STZ-induced diabetes--associated decrease described by Garrett et al. was attenuated by treatment with LA. On the other hand, Ahmad et al. ([@B57]) analyzed the femoral and tibial marrow and determined that 8 months of T2D significantly decreased NPY, as expected with longer durations of diabetes. They attributed loss of NPY to both neuronal and nonneuronal (i.e., megakaryocytes) sources. While the literature is divided between studies that reveal increased and decreased NPY with diabetes, the duration of diabetes, not the type, seems to be most accountable for the direction of change.

Another unexpected finding was that bone marrow adiposity was significantly decreased in the DM compared with the Con group but was increased with treatment in the Ile and Ins + Menh groups. Bone marrow adipose is proposed to have mixed white and brown fat characteristics ([@B58],[@B59]). It has been hypothesized that the brown adipose-like phenotype provides energy for hematopoietic and mesenchymal compartments ([@B60]). Acting as autocrine/paracrine/endocrine support, lipid-filled adipocytes in the bone marrow repress growth and differentiation of hematopoietic stem cells ([@B61],[@B62]) and have been considered negative regulators of the hematopoietic niche ([@B60],[@B63]). This suppressive activity has been primarily attributed to the reduced production of GM-CSF and granulocyte colony-stimulating factor and increased secretion of neuropilin and lipocalin-2 ([@B61],[@B64]). This is also consistent with our finding that DM was associated with decreased marrow adiposity and increased GM-CSF.

This study demonstrates that the bone marrow may be a therapeutic target. We showed that early in STZ-induced diabetes, the bone marrow is characterized by an increased proportion of strong-positive immunoreactivity for TH, SST, and NPY; decreased bone marrow adiposity; a highly proinflammatory bone marrow microenvironment; and increased proinflammatory gene expression in bone marrow--derived progenitor cells. Vasopeptidase inhibition or combination treatments to inhibit aldose reductase and decrease oxidative stress or supplementation with ω-3 PUFAs and insulin prevented functional neuronal defects and damage to the bone marrow caused by STZ-induced diabetes. Follow-up studies of these therapeutic strategies should include assessment of progenitor cell function and examination in T2D models. Furthermore, in a clinical setting, these treatment conditions could be combined (e.g., Ins + Fid + Ile + LA), and determining whether an additive effect exists will be important because these agents address independent pathways known to be dysfunctional in diabetes.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0433/-/DC1>.
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